Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced Clot: A feasibility evaluation

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 3, 2010, Pages 337-344

  Cellai, Anna Paola ^a   Lami, Donatella ^b   Magi, Alberto ^b   Liotta, Agatina Alessandrello ^a   Rogolino, Angela ^a   Antonucci, Emilia ^b   Bandinelli, Brunella ^b   Abbate, Rosanna ^b   Prisco, Domenico ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clot lysis time; Fibrinolysis; PAI 1 antigen; T Pa; TAFI

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGING; ANALYTIC METHOD; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; EVALUATION; FEASIBILITY STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; MATHEMATICAL ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TURBIDITY;

ADULT; AGE FACTORS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALCIUM CHLORIDE; CARBOXYPEPTIDASE U; CARRIER PROTEINS; FEASIBILITY STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PHOSPHOLIPIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TIME FACTORS; YOUNG ADULT;

EID: 77953647952     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608325542     Document Type: Article

References (21)

1. Mutch NJ, Thomas L., Moore NR, Lisiak KM, Booth NA TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J. Thromb Haemost. 2007 ; 5: 812-817.
2. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 1991 ; 151: 1721-1731.
3. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res. 2003 ; 112: 329-337.
4. Lisman T., de Groot PG, Meijers JC, Rosendaal FR Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005 ; 105: 1102-1105.
5. Meltzer ME, Lisman T., Doggen CJ, de Groot PG, Rosendaal FR Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous Thrombosis. PLoS. Med. 2008 ; 5: e97.
6. Lisman T., Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001 ; 121: 131-139.
7. Von dem Borne PA, Bajzar L., Meijers JC, Nesheim ME, Bouma BN Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997 ; 99: 2323-2327.
8. Mosnier LO, Lisman T., Van den Berg HM, Nieuwenhuis HK, Meijers JCM, Bouma BN The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost. 2001 ; 86: 1035-1039.
9. Lisman T., Mosnier LO, Lambert T., Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood. 2002 ; 99: 175-179.
10. Colucci M., Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003 ; 38: 230-237.
11. Klement P., Liao P., Bajzar L. A novel approach to arterial thrombolysis. Blood. 1999 ; 94: 2735-2743.
12. Stromqvist M., Schatteman K., Leurs J., et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost. 2001 ; 85: 12-17.
13. Colucci M., Binetti BM, Tripodi A., Chantarangkul V., Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood. 2004 ; 103: 2157-2161.
14. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004 ; 5: R80.
15. Fr̀re C., Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study. Blood. 2006 ; 108: 1562-1568.
16. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006 ; 60: 144-151.
17. Lahlou-Laforet K., Alhenc-Gelas M., Pornin M., et al. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease. Am J Cardiol. 2006 ; 97: 1287-1291.
18. Asselbergs FW, Williams SM, Hebert PR, et al. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost. 2007 ; 5: 313-320.
19. Chetaille P., Alessi MC, Kouassi D., Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 2000 ; 83: 902-905.
20. Juhan-Vague I., Renucci JF, Grimaux M., et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000 ; 20: 2156-2161.
21. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN Plasma TAFI levels influence the CLT in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998 ; 80: 829-835.